Evermil 5mg Tablet

• Breast Cancer
• Kidney Cancer
• Neuroendocrine Tumors (NET)
• Organ Transplant
• Tuberous Sclerosis

The human body shows undesired symptoms after taking Evermil 5mg Tablet. Usually, they disappear with time as the body adjusts to the medicine. It is advised to consult your doctor if these symptoms become unmanageable. Some of the side effects of Evermil Tablet are mentioned below:

• ​Difficulty breathing or swallowing
  
• Swelling of the face, lips, tongue, or throat
  
• Severe itching, red rash, or raised bumps
  
• Infection (chills, fever, or recurrent illness)
  
• Coughing, wheezing, or breathlessness
  
• Excessive thirst or abnormal urine output (too high or too low)
• Tiredness or fatigue
• Bleeding episodes
• Increased appetite with weight loss
  
• Elevated liver enzymes (alanine aminotransferase)
  
• High triglyceride levels in the blood
  
• Joint pain
  
• Pleural effusion (fluid around the lungs)
  
• Pulmonary edema (fluid in the lungs)
  
• Stomatitis (mouth inflammation or sores)
  
• Anemia (low red blood cell count)
  
• Low potassium levels in the blood
  
• Weight loss
  
• Changes in taste
• Rash or skin irritation
  
• Diarrhea
  
• Low blood platelets
  
• High blood sugar (increased glucose levels)
  
• Decreased appetite

As directed by your physician, take this medication according to the prescription. Swallow the whole tablet with water. Avoid chewing, crushing, or breaking it. It is preferable to take the Evermil 5 Tablet at a set time, but it can be taken after or without food. 

Evermil 5mg Tablet works by stopping the activity of a protein known as a mammalian target of rapamycin (mTOR). This protein is responsible for cell growth and division. Evermil Tablet slows down the growth of cancerous cells by blocking the production of the mTOR protein. It also reduces the size of the tumor and prevents cancer from spreading to other parts of the body.

It is advised not to miss any scheduled dosage of the Evermil 5 mg Tablet. In case you miss a dose, consult your doctor immediately. Don't overdose to compensate for the missed one. 

• Mouth sores are the most common side effect, so doctors often recommend using a dexamethasone oral rinse (instead of alcohol-based mouthwash) to help prevent them.
• Infections can happen more easily while on treatment, so it’s important to watch for signs like fever or chills.
• Non-infectious pneumonitis, which is lung inflammation not caused by infection, is a unique and serious side effect of mTOR inhibitors; it may require lowering the dose or even stopping the medicine.
• Metabolic changes such as high blood sugar or cholesterol levels can occur, so regular monitoring is advised.
  
• It is advised to use effective birth control ways and avoid pregnancy during the treatment with the Evermil 5 mg Tablet.
• A person should avoid smoking while undergoing treatment with the Evermil 5 mg Tablet. Smoking may reduce the effectiveness of medicine.
• Monitor your blood sugar & pressure, kidney & liver function (KFT & LFT), and heart function at proper intervals after taking the Evermil 5 mg Tablet.
• Swelling of hands and lips and weight gain are some of the side effects observed after taking the Evermil 5 mg Tablet. To reduce them, the doctor may suggest some medication.
• Skin becomes extremely sensitive after taking the Evermil 5 mg Tablet. It is advised to cover your skin exposed to direct sun rays and use high SPF sunscreen before going out.
• It is advised to avoid taking analgesics/antacids (medicines used to neutralize the stomach acid) while taking the Evermil 5 mg Tablet, as it may reduce the effectiveness of the medicine.
• Keep your body hydrated, as diarrhea is one of the common side effects experienced after taking the Evermil 5 mg Tablet. Consult your doctor if it doesn't stop or if blood appears in your stools.
• In case you notice symptoms like blurred vision, difficulty breathing, cough & fever, and diarrhea while taking the Evermil 5 mg Tablet, consult your doctor immediately before these symptoms become severe.

At our pharmacy, your health is our top priority. All of our medicines are safe, effective, and approved by leading health authorities. We partner exclusively with reliable and reputable manufacturers, ensuring the highest quality standards in every product we deliver.

Enjoy the convenience of fast home delivery, secure packaging, and affordable prices—plus special discounts on bulk orders. We’re proud to offer international shipping to a wide range of countries across Asia, Europe, Africa, the Americas, and beyond, making trusted healthcare accessible no matter where you are.

Whether you're a patient or a healthcare provider, you can order with confidence and compassion. Our goal is to ensure that quality healthcare reaches everyone, everywhere.


We currently ship to:

Barbados, Haiti, Trinidad and Tobago, Mexico, Bahamas, Ecuador, Peru, Chile, Brazil, Colombia, Philippines, U.K., USA, Kuwait, Saudi Arabia, UAE, Oman, Qatar, Japan, Ireland, Russia, China, France, Australia, Lithuania, Nigeria, Romania, Algeria, Canada, Singapore, Thailand, Hong Kong, Bahrain, Jordan, Indonesia, Hungary, Moldova, Bulgaria, Azerbaijan, Congo, Ethiopia, Lebanon, Morocco, Mozambique, South Korea, Sri Lanka, Belarus, Mongolia, Malaysia, Vietnam, Tunisia, Zambia, and Israel.
Experience the quality everyone’s talking about – order today!

• Bengueddache, S., Cook, M., Lehmann, S., Arroyo, D., Togni, M., Puricel, S., & Cook, S. (2024). Ten-year clinical outcomes of everolimus- and biolimus-eluting coronary stents vs. Everolimus-eluting bioresorbable vascular scaffolds—Insights from the EVERBIO-2 trial. Frontiers in Cardiovascular Medicine, 11(4), 1426348 -  https://pubmed.ncbi.nlm.nih.gov/39323753/
• Bingqi Zhuang, Chongning Zhong, Yuting Ma, Ao Wang, Hailian Quan, Lan Hong (2024). Innovative Therapeutic Strategies for Myocardial Infarction Across Various Stages: Non-Coding RNA and Stem Cells, International Journal of Molecular Sciences, 10.3390/ijms26010231, 26, 1, (231) - https://pmc.ncbi.nlm.nih.gov/articles/PMC11720039/
• De Simone, P., Precisi, A., Lai, Q., Ducci, J., Campani, D., Marchetti, P., & Gitto, S. (2024). Everolimus Mitigates the Risk of Hepatocellular Carcinoma Recurrence after Liver Transplantation. Cancers, 16(7), 1243 - https://pubmed.ncbi.nlm.nih.gov/38610921/
• Fort-Casamartina, E., Pernas, S., Otero, S., Mate, P., Gonzalo, N., Narváez, S., Rigo-Bonnin, R., Padró-Miquel, A., Teulé, À., Garcia del Muro, X., Peiró, I., Arribas, L., Esteve, A., Gonzalez, A., Rey, M., Clopés, A., Fontanals, S., & Muñoz, C. (2025). Everolimus Through Plasmatic Concentrations in Cancer Patients: Prospective Longitudinal Observational Multicentric Study (DIANA-1 Project). Journal of Clinical Medicine, 14(1), 145 - https://www.mdpi.com/2077-0383/14/1/145
• Gulati S, Tangen C, Ryan CW, et al. (2024) Adjuvant Everolimus in Non–Clear Cell Renal Cell Carcinoma: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open.7(8):e2425288 - https://pubmed.ncbi.nlm.nih.gov/39106067/
• Powles, T., Choueiri, T. K., Albiges, L., Peltola, K., de Velasco, G., Burotto, M., Suarez, C., Ghatalia, P., Iacovelli, R., Lam, E. T., Verzoni, E., Gümüş, M., Stadler, W. M., Kollmannsberger, C., Melichar, B., Venugopal, B., Gross‑Goupil, M., Poprach, A., De Santis, M., Rizzo, M., Shinde, R., Saretsky, T. L., He, L., Perini, R. F., & Vickery, D. (2025). Health‑related quality of life with belzutifan versus everolimus for advanced renal cell carcinoma (LITESPARK‑005): Patient‑reported outcomes from a randomized, open‑label, phase 3 trial. Lancet Oncology, 26(4), 491–502.
• Saliba F, Duvoux C, Dharancy S, Dumortier J, Calmus Y, Gugenheim J, Kamar N, Salamé E, Neau-Cransac M, Vanlemmens C, Durand F, Pageaux GP, Hardwigsen J, Benkhatar Y, Derquenne F, Conti F. (2025) Five-year outcomes in liver transplant patients receiving everolimus with or without a calcineurin inhibitor: Results from the CERTITUDE study. Liver Int. Nov;42(11):2513-2523.
• Taboada, R. G., Brito, A. B., Silva, A. L., Weschenfelder, R. F., & Riechelmann, R. P. (2024). The Efficacy of a Lower Dose of Everolimus in Patients with Advanced Neuroendocrine Tumors. Cancers, 16(22), 3773.